Merus N.V. (MRUS) Analysts See $-0.93 EPS on April, 25

Investors wait Merus N.V. (NASDAQ:MRUS)’s quarterly earnings on April, 25., as reported by RTT. earnings per share of $-0.93 is 8.14 % down from 2018’s $-0.86 EPS. Analysts at Wall Street see Merus N.V.’s 69.09 % negative EPS growth compared to $-0.55 earnings per share for previous quarter. The stock increased 1.27% or $0.16 during the last trading session, hitting $12.75.Currently Merus N.V. is downtrending after 28.39% change in last March 29, 2018. MRUS has 6,770 shares volume. MRUS underperformed by 32.76% the S&P500.

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics.The company has $289.87 million market cap. The Company’s lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers.Currently it has negative earnings. The firm also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies, as well as developing MCLA-158, a bispecific antibody candidate, which is designed to bind to cancer stem cells for the potential treatment of colorectal cancer.

For more Merus N.V. (NASDAQ:MRUS) news announced recently go to: Benzinga.com, Globenewswire.com, Globenewswire.com, 247Wallst.com or Seekingalpha.com. The titles are as follows: “Most Notable Abstracts Released Ahead Of ASCO 2017 – Benzinga” announced on May 19, 2017, “Merus to Present at the Cowen & Co. 38th Annual Health Care Conference – GlobeNewswire” on March 06, 2018, “Merus to Present at the Jefferies 2018 Healthcare Conference – GlobeNewswire” with a publish date: May 31, 2018, “Major Biopharma Catalysts on October’s FDA Calendar – 24/7 Wall St.” and the last “Merus: A Buy On Lucrative Incyte Partnership And 2017 Catalysts – Seeking Alpha” with publication date: May 05, 2017.

Merus N.V. (NASDAQ:MRUS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.